High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Authors
Cook, GWilliams, C
Brown, J
Cairns, D
Cavenagh, J
Snowden, J
Ashcroft, A
Fletcher, M
Parrish, C
Yong, K
Cavet, James
Hunter, H
Bird, J
Chalmers, A
O'Connor, S
Drayson, M
Morris, T
Affiliation
St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, UK.Issue Date
2014-07
Metadata
Show full item recordAbstract
Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined. We aimed to compare high-dose melphalan plus salvage ASCT with cyclophosphamide in patients with relapsed multiple myeloma who had previously undergone ASCT.Citation
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. 2014, 15 (8):874-85 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(14)70245-1PubMed ID
24948586Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(14)70245-1